Research graph
References from Implementation of Rapid CYP2C19 Genotyping to Guide Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack. Local targets link to admitted publications; unresolved targets remain external evidence.
2026 heart disease and stroke statistics: a report of US and global data from the American Heart Association
10.1161/cir.0000000000001412 · 2026 · External reference
2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association
10.1161/str.0000000000000375 · 2021 · External reference
Unresolved reference
External reference
Association between CYP2C19 loss‐of‐function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack
10.1001/jama.2016.8662 · 2016 · External reference
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes
10.1016/j.jacc.2007.07.058 · 2007 · External reference
Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA
10.1056/nejmoa1916870 · 2020 · External reference
Ticagrelor versus clopidogrel in CYP2C19 loss‐of‐function carriers with stroke or TIA
10.1056/nejmoa2111749 · 2021 · External reference
CYP2C19 genetic testing for Oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association
10.1161/cir.0000000000001257 · 2024 · External reference
Pharmacogenetics in practice: estimating the clinical actionability of pharmacogenetic testing in perioperative and ambulatory settings
10.1111/cts.12748 · 2020 · External reference
Unresolved reference
External reference
Recommendations for clinical CYP2C19 genotyping allele selection: a report of the Association for Molecular Pathology
10.1016/j.jmoldx.2018.01.011 · 2018 · External reference
Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update
10.1002/cpt.2526 · 2022 · External reference
Clopidogrel with aspirin in high‐risk patients with acute non‐disabling cerebrovascular events II (CHANCE‐2): rationale and design of a multicentre randomised trial
10.1136/svn-2020-000791 · 2021 · External reference
Characteristics, performance measures, and in‐hospital outcomes of the first one million stroke and transient ischemic attack admissions in get with the guidelines‐stroke
10.1161/circoutcomes.109.921858 · 2010 · External reference
Unresolved reference
External reference
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
10.1056/nejm199309023291001 · 1993 · External reference
Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda
10.1007/s10488-010-0319-7 · 2011 · External reference
Implementing CYP2C19‐guided clopidogrel therapy: a scoping review of pharmacogenomic testing services
10.1038/s41397-025-00371-4 · 2025 · External reference
10.1161/str.0000000000000513
10.1161/str.0000000000000513 · External reference
Expansion of Telestroke coverage in community hospitals: unifying stroke care and reducing transfer rate
10.1002/ana.26839 · 2024 · External reference
Association of hospital telestroke adoption with changes in initial hospital presentation and transfers among patients with stroke and transient ischemic attacks
10.1001/jamanetworkopen.2021.26612 · 2021 · External reference
Pharmacist use of a population management dashboard for safe anticoagulant prescribing: evaluation of a Nationwide implementation effort
10.1161/jaha.124.035859 · 2024 · External reference
Pharmacogenomic clinical decision support: a scoping review
10.1002/cpt.2711 · 2022 · External reference
Pharmacogenomic clinical decision support: a review, how‐to guide, and future vision
10.1002/cpt.2387 · 2021 · External reference
A genotype‐guided strategy for Oral P2Y(12) inhibitors in primary PCI
10.1056/nejmoa1907096 · 2019 · External reference
Cost‐effectiveness of testing for CYP2C19 loss‐of‐function carriers following transient ischemic attack/minor stroke: a Canadian perspective
10.1177/17474930221111898 · 2023 · External reference
Cost‐effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high‐risk transient ischemic attack
10.1038/s41598-021-86824-9 · 2021 · External reference
Clinical and cost‐effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model
10.3310/pwcb4016 · 2024 · External reference
Expanding evidence leads to new pharmacogenomics payer coverage
10.1038/s41436-021-01117-w · 2021 · External reference
Progress in pharmacogenomics implementation in the United States: barrier erosion and remaining challenges
10.1002/cpt.3736 · 2025 · External reference
